These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 18458647)

  • 21. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New pertussis vaccination approaches: en route to protect newborns?
    Locht C; Mielcarek N
    FEMS Immunol Med Microbiol; 2012 Nov; 66(2):121-33. PubMed ID: 22574832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tolerance of acellular pertussis vaccine booster injection in 15-20-month-old children].
    Mallet E; Puyt A; Arson S; Surbled V
    Arch Pediatr; 2000 Apr; 7(4):410-4. PubMed ID: 10793931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
    Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
    Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible options for new pertussis vaccines.
    Meade BD; Plotkin SA; Locht C
    J Infect Dis; 2014 Apr; 209 Suppl 1():S24-7. PubMed ID: 24626868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Licensed pertussis vaccines in the United States. History and current state.
    Klein NP
    Hum Vaccin Immunother; 2014; 10(9):2684-90. PubMed ID: 25483496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention of pertussis and high expectations concerning vaccines].
    Wysocki J
    Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand.
    Radke S; Petousis-Harris H; Watson D; Gentles D; Turner N
    Vaccine; 2017 Jan; 35(1):177-183. PubMed ID: 27866766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pertussis: data collection and vaccinal strategy].
    Bonmarin I; Bouraoui L; Guiso N; Levy-Bruhl D
    Med Mal Infect; 2009 May; 39(5):271-7. PubMed ID: 19362438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
    Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J
    Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pertussis vaccines: WHO position paper - September 2015.
    Wkly Epidemiol Rec; 2015 Aug; 90(35):433-58. PubMed ID: 26320265
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.
    Hviid A; Stellfeld M; Andersen PH; Wohlfahrt J; Melbye M
    Vaccine; 2004 Sep; 22(27-28):3530-4. PubMed ID: 15315832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What's wrong with acellular pertussis vaccines?
    Wiedermann BL
    Clin Ther; 2013 Feb; 35(2):115-8. PubMed ID: 23375491
    [No Abstract]   [Full Text] [Related]  

  • 35. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.
    Lavine JS; Bjørnstad ON; de Blasio BF; Storsaeter J
    Vaccine; 2012 Jan; 30(3):544-51. PubMed ID: 22119924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of acellular pertussis vaccination during childhood (<7 years of age) for preventing pertussis in household contacts 1-9 years old in Catalonia and Navarra (Spain).
    Plans P; Toledo D; Sala MR; Camps N; Villanova M; Rodríguez R; Alvarez J; Solano R; García-Cenoz M; Barrabeig I; Godoy P; Minguell S
    Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):2059-2067. PubMed ID: 27612470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
    Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
    APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response.
    Rieber N; Graf A; Hartl D; Urschel S; Belohradsky BH; Liese J
    PLoS One; 2011 Mar; 6(3):e17271. PubMed ID: 21408149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postlicensure epidemiology of childhood vaccination: the Danish experience.
    Hviid A
    Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
    Kuno-Sakai H; Kimura M; Watanabe H
    Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.